Canixin DHPPi/L Suspension for Injection for Dogs (50 dose)

Target species Dog Indications for use For active immunisation of dogs from 8 weeks of age to: - prevent mortality and clinical signs caused by canine distemper virus; - prevent mortality and clinical signs caused by canine adenovirus type 1; - prevent clinical signs and mortality and reduce excretion caused by canine parvovirus in challenge studies performed with a CPV-2b strain; - prevent clinical signs and reduce excretion caused by canine parvovirus in a challenge study performed with a CPV-2c strain; - reduce respiratory clinical signs and viral excretion caused by canine parainfluenza virus and canine adenovirus type 2; - prevent mortality and reduce infection, clinical signs, kidney colonisation, renal lesions and urine shedding of L. canicola; - reduce infection, clinical signs, kidney colonisation and urine shedding of L. icterohaemorrhagiae; Onset of immunity: The onset of immunity has been demonstrated from 3 weeks after the primary vaccination for CDV, CAV-2 and CPV, 4 weeks for CAV-1 and CPiV, 5 weeks for L. canicola and 2 weeks for L. icterohaemorrhagiae. Duration of immunity: After the primary vaccination course, the duration of immunity lasts for one year for all components. After the annual booster, the duration of immunity lasts for 3 years for CDV, CAV-1, CAV-2 and CPV. In the duration of immunity studies one year after the basic vaccination scheme there was no significant difference between vaccinated and control dogs in viral excretion for CPiV and CAV-2, in reduction of kidney colonisation for L. Canicola and L. icterohaemorrhagiae, nor in renal lesions and urine shedding for L. Canicola. For CAV-2, the duration of immunity after the annual booster was not established by challenge, and is based on the presence of CAV-2 antibodies 3 years after the booster vaccination. Contra-indications None Special warnings for each target species After vaccination, the live viral vaccinal strains (CAV-2, CPV) can be spread to unvaccinated animals without any pathological effect for these in-contact animals. The presence of maternally derived antibodies (puppies from vaccinated females) can interfere with the vaccination. Therefore the vaccination scheme should be adapted accordingly. Special precautions for use i. Special precautions for use in animals Vaccinate only healthy animals ii.Special precautions to be taken by the person administering the veterinary medicinal product to animals -In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Adverse reactions After the administration of one dose of the product, a moderate local reaction which resolves spontaneously within 1 to 2 weeks may commonly be observed. This transient local reaction can be a swelling (≤ 4 cm) or slight diffuse local oedema, in rare cases associated with pain or pruritus. Some transient post-vaccinal lethargic states are common. In rare cases hyperthermia or digestive disturbances such as anorexia, diarrhoea or vomiting may occur. Very rare hypersensitivity reactions have been reported, in case of such an allergic or anaphylactic reaction, appropriate symptomatic treatment should be administered. Use during pregnancy, lactation or lay Do not use during pregnancy and lactation. Interactions No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.
Vat Rate: 20%